ModernGraham Annual Valuation Of Cardinal Health Inc.
Summary
- CAH is not suitable for either Defensive Investors or Enterprising Investors following the ModernGraham approach.
- According to the ModernGraham valuation model, the company is overvalued at the present time.
- The market is implying 9.01% earnings growth over the next 7-10 years, which is not supported by the rate the company has achieved in recent years.
Cardinal Health Inc. (NYSE:CAH) may attract some investors because it has easily beat the market over the last few years, leading some investors to believe it must therefore be a good buy. However, Benjamin Graham, the father of value investing, taught that the sole factor in investment decisions as the most important aspect to consider is whether the company is trading at a discount relative to its intrinsic value. It is through a thorough fundamental analysis that the investor is able to make a determination about a potential investment's merits. Here is a look at how Cardinal Health Inc. fares in the ModernGraham valuation model.
The model is inspired by the teachings of Benjamin Graham and considers numerous metrics intended to help the investor reduce risk levels. The first part of the analysis is to determine whether the company is suitable for the very conservative Defensive Investor or the less conservative Enterprising Investor, who is willing to spend a greater amount of time conducting further research.
In addition, Graham strongly suggested that investors avoid speculation in order to remove the subjective elements of emotion. This is best achieved by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company. By using the ModernGraham method one can review a company's historical accomplishments and determine an intrinsic value that can be compared across industries.
Defensive Investor - must pass at least 6 of the following 7 tests: Score = 3/7
- Adequate Size of Enterprise - market capitalization of at least $2 billion - PASS
- Sufficiently Strong Financial Condition - current ratio greater than 2 - FAIL
- Earnings Stability - positive earnings per share for at least 10 straight years - PASS
- Dividend Record - has paid a dividend for at least 10 straight years - PASS
- Earnings Growth - earnings per share has increased by at least 1/3 over the last 10 years using 3-year averages at beginning and end of period - FAIL
- Moderate PEmg (price over normalized earnings) ratio - PEmg is less than 20 - FAIL
- Moderate Price to Assets - PB ratio is less than 2.5 or PB x PEmg is less than 50 - FAIL
Enterprising Investor - must pass at least 4 of the following 5 tests or be suitable for a defensive investor: Score = 3/5
- Sufficiently Strong Financial Condition, Part 1 - current ratio greater than 1.5 - FAIL
- Sufficiently Strong Financial Condition, Part 2 - Debt to Net Current Assets ratio less than 1.1 - FAIL
- Earnings Stability - positive earnings per share for at least 5 years - PASS
- Dividend Record - currently pays a dividend - PASS
- Earnings growth - EPSmg greater than 5 years ago - PASS
Valuation Summary
Key Data:
| Recent Price | $81.74 |
| MG Value | $35.17 |
| MG Opinion | Overvalued |
| Value Based on 3% Growth | $44.68 |
| Value Based on 0% Growth | $26.19 |
| Market Implied Growth Rate | 9.01% |
| Net Current Asset Value (NCAV) | -$5.64 |
| PEmg | 26.53 |
| Current Ratio | 1.18 |
| PB Ratio | 4.44 |
Balance Sheet - September 2014
| Current Assets | $17,538,000,000 |
| Current Liabilities | $14,896,000,000 |
| Total Debt | $3,164,000,000 |
| Total Assets | $25,711,000,000 |
| Intangible Assets | $5,923,000,000 |
| Total Liabilities | $19,455,000,000 |
| Outstanding Shares | 340,000,000 |
Earnings Per Share
| 2015 (estimate) | $4.19 |
| 2014 | $3.38 |
| 2013 | $0.97 |
| 2012 | $3.06 |
| 2011 | $2.72 |
| 2010 | $1.77 |
| 2009 | $3.18 |
| 2008 | $3.57 |
| 2007 | $4.77 |
| 2006 | $2.33 |
| 2005 | $2.41 |
Earnings Per Share - ModernGraham
| 2015 (estimate) | $3.08 |
| 2014 | $2.48 |
| 2013 | $2.13 |
| 2012 | $2.76 |
| 2011 | $2.81 |
| 2010 | $2.94 |
Dividend History
CAH Dividend data by YCharts
Conclusion:
Cardinal Health does not qualify for either the Defensive Investor or the Enterprising Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and high PEmg and PB ratios. The Enterprising Investor takes issue with the level of debt relative to the current assets. As a result, any purchase of the company is made with a speculative nature behind it. That said, any speculator interested in pursuing the company should still proceed to the next part of the analysis, which is a determination of the company's intrinsic value.
With regard to that intrinsic value, the company has grown its EPSmg (normalized earnings) from $2.81 in 2011 to only an estimated $3.08 for 2015. This level of demonstrated growth does not support the market's implied estimate for earnings growth of 9.01% over the next 7-10 years. In fact, actual growth has been closer to 1.94% in recent years. The ModernGraham valuation model therefore returns an estimate of intrinsic value below the current price, indicating the company is overvalued at the present time.
This article was written by
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.